DNDI-6174
Develop DNDI-6174 as a new chemical entity for the treatment of visceral leishmaniasis with the aim of bringing an additional entity with a novel mechanism of action to the visceral leishmaniasis portfolio; and potentially for the treatment of cutaneous leishmaniasis
current phase of drug development
updated 1 Mar 2022
Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019. DNDI-6174 presents a new mode of action among compounds in DNDi’s leishmaniasis portfolio, as well as a predicted low human dose and a very promising safety margin.
Project updates
2021
2021 saw progress made on the drug substance with the selection of an HBr salt that showed very good solubility, scalability, and manufacturability properties. Moreover, the former synthetic route has been optimized and a reproducible process has been established, increasing throughput and reducing cost of goods. Pre-clinical activities have started with the selection of CRO partner Aptuit, an Evotec Company, and the development of the non-clinical formulation.
2020
Further characterization of DNDI-6174 and preparations to initiate pre-clinical activities continued in 2020. With support from Japan’s Global Health Innovative Technology Fund (GHIT Fund), DNDi and Eisai will start collaborating in Q2 2021 to conduct pre-clinical development activities and prepare the way for future Phase I clinical studies in healthy human volunteers.
2019
Planning is underway to start pre-clinical activities in 2020.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
